Morphosys is a leading biotechnology developing therapeutic antibodies for a range of different indications.
The company is behind the very successful HuCAL antibody library technology which generates one of the fastest drug classes currently available. Antibody treatments focus upon oncology, rheumatoid arthritis and Alzheimer’s disease amongst many others.
Morphosys currently has more than 90 antibody programs in development, 20 of which are in clinical trials and many of which are partnered up with big pharmaceutical companies.
Figure 1: Number of antibody candidates being partnered with big pharma
GlaxoSmithkline partners alongside Morphosys on of of it's lead product MOR103 which is an antibody that works against GM-CSF which is indicated for the treatment of rheumatoid arthritis and multiple sclerosis. MOR 202, also an advanced candidate is being developed in partnership with big biotech company Celgene for the treatment of patients with multiple myeloma.
Other candidates generating interest for the company and being developed by major companies are Gantenerumab, an antibody under development by Roche for Alzheimer’s disease and Guselkumab an anti inflammatory being developed by Janssen Biotech.
Even though Morphosys has partaken in many partnerships, it has only been involved in one M&A and that was the acquisition of Sloning Biotechnology for $26.5 milion in 2010, which enabled the company to get access to it's combinatorial protein Slonomics platform.
Strong partnering partner
Morphosys is a clear partner of choice for those focused in antibody discovery. The company already has an impressive list of partners and is looking to expand on this. Morphosys offers a rich pipeline of antibody candidates that are great partnering prospects for companies and it is open to discussing these clinical proprietary programs with any interested companies. On the flip side Morphosys is keen to increase its own capabilities and is therefore also looking to source antibodies and other biomolecules at late stage or early clinical stages for in-licensing or co-development. Any companies who have innovative technology platforms may also propose these to Morphosys for potential collaboration.
Morphosys should be contacted before submitting any proposals as it has a specific procedure which companies should follow in order to keep their products/technologies confidential.
Morphosys is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Morphosys presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
- ASH Annual Meeting
For a full list of forthcoming partnering events where you could meet with Morphosys in person visit Current Partnering’s Event calendar.
Contacting Morphosys for partnering
Morphosys can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Morphosys' business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Morphosys website has details for contacting Morphosys.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Morphosys' business development executives have LinkedIn profiles and can be found by viewing the company’s profile.
Visit Morphosys Linkedin Page.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the contacts page on the Morphosys' website for potential partnering opportunities and general contact names.
Our report provides more detailed insight into the details of each deal.
See: Report: Partnering Agreements with MorphoSys 2009-2014
MorphoSys partnering at Current Agreements
Full details on each deal can be found at CurrentAgreements (subscription required)
Or purchase report: Report: Partnering Agreements with MorphoSys 2009-2014
Available reports from Current Partnering
Report: Partnering Agreements with MorphoSys 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for MorphoSys
Read: more on MorphoSys company profile, recent partnering, M&A and financing news and articles
Report: Finding Biopharma Licensing and Collaboration Partners
View: CP Insight’s Partnering Scorecard – view top life science partnering deals by value
View: CP Insight’s M&A Scorecard – view top life science M&A deals by value
View: CP Insight Deal Monitor’s Deal Metrics – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Activity – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Activity- latest trends in big biotech deal making activity
View: CP Insight’s Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: CP Insights’s Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk